The Right Mouse Model Is Crucial for Huntington’s Disease Drug Development

Scientists evaluated mouse models used for developing new treatments for mood disorders associated with Huntington's disease and recommend which are most relevant and have greater potential for success

December 11, 2019 - Amsterdam, NL – Huntington's disease (HD) is an incurable and fatal hereditary disease. Developing disease-modifying drugs to treat patients with HD depends on studying them in animal models. Scientists evaluated the mouse models used for developing new treatments for mood disorders in HD and recommended which of these models are most relevant to their studies. Their findings are published in the Journal of Huntington's Disease. More...

December 11, 2019

Huntington’s Disease Patients Need Better Understanding of Risks and Benefits of Clinical Trials

Investigators report in JHD that Huntington’s disease patients are at risk for therapeutic misconception about clinical trials and recommend improving patient-doctor communications to ensure patients understand how trials differ from clinical care

December 10, 2019 - Amsterdam, NL – For patients with Huntington's disease (HD), clinical trials can offer hope when there are no treatments available despite unknowns about whether the therapy will work or is safe. A new study in the Journal of Huntington's Disease found that although the HD community appears highly optimistic about HD research, patients are at risk for therapeutic misconception. In order to allay patients' misgivings, investigators recommend improvements to patient-doctor communication to better convey trial goals, risks and benefits. More...

December 10, 2019

New Study Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-Moderate Alzheimer’s Disease

November 27, 2019 - Aberdeen, UK and Singapore, Singapore – In a paper published in today's online issue of the Journal of Alzheimer's Disease, TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease. These results showed that, even at the lowest dose of hydromethylthionine previously tested in two Phase 3 global clinical trials (8 mg/day), the drug produced concentration-dependent effects on cognitive decline and brain atrophy. More...

November 27, 2019

Psychological Well-Being at 52 Years Could Impact on Cognitive Functioning at 69 Years

November 26, 2019 - Tokyo, Japan – People around the world are living longer, and dementia has consequently become recognized as a public health priority in many countries. The Lancet Commission paper in 2017 collated a large body of medical research evidence that aims to address the dementia epidemic and following challenge for health and social care. It is estimated that as much as 35% of dementia cases could be prevented by targeting nine modifiable risk factors. However, relatively little is known about psychological well-being in this context. More...

November 26, 2019